Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery System; Company is Currently Conducting Additional Studies into New and Previously Untested KRAS Mutation with Results expected in the Near FutureGrand Cayman, Cayman Islands, July 09, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cance ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 KRAS 基因的错义突变常常导致其持续激活，从而引发下游信号级联失调，进而驱动肿瘤发生。 KRAS 基因突变存在于近 25%的人类癌症中，并且在一些最常见 的癌症类型中频繁出现，例如 肺癌 （35%） 、 结直肠癌 （49%） 和 胰腺腺癌 （92%） 。 在所有的 KRAS 基因突变中， KRAS G12D 、 KRAS G12V 、 KRAS G12C 最为常见，分别占比 29%、 23% 和 15%。一直以来，KRAS 被认为是难成药靶点， 直到最近才有两款小分子抑制剂获批上市， 分别是 索托拉西布 （ sotorasib ） 和阿达格拉西布 （ adagrasib ） ，均靶向抑制 KRAS G12C ， 这也意味着， 更 多的 KRAS 基因突变仍无药可用，因此，迫切需要开发 能够靶向 KRAS G12C 以外突变的特异性抑制剂。 2025 年 6 月 19 日，EnFuego 公司和北卡罗来纳大学教堂山分校的研究人员合作，在 Cell 子刊 Cancer Cell 上发表了题为： A first-in-class EGFR-directed KRAS G12 ...

DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Instil's wholly-owned subsidiary dedicated to the development of AXN-2510 ("'2510"), a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer (NSCLC). About Ax ...

Key Takeaways ALNY secured EC approval to expand Amvuttra's use to treat ATTR-CM in adult patients. Approval was based on HELIOS-B data showing mortality, CV event and symptom improvement. Amvuttra is now the first RNAi therapy approved in the EU for both ATTR-CM and hATTR-PN.Alnylam Pharmaceuticals, Inc. (ALNY) announced that the European Commission (EC) has approved a label expansion of its RNAi therapeutic Amvuttra.The EC has now approved Amvuttra for the treatment of wild-type or hereditary transthyre ...

Alnylam Pharmaceuticals (ALNY) FY Conference June 09, 2025 09:20 AM ET Speaker0 Great. Good morning, everyone. Thank you so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. We're really pleased to be joined by the Alnylam team. With me, we have Yvonne Greenstreet, CEO, and John Kennedy, head of the TTR franchise. So Yvonne, before we even start, you know, you announced some news this morning, so maybe this is a perfect time point to maybe speak to the European approval that ...

Core Insights - Bio-Path Holdings, Inc. is a clinical-stage biotechnology company focused on RNA interference therapeutics using its DNAbilize® platform [1] - The lead candidate, prexigebersen (BP1001), is in Phase 2 trials for acute myeloid leukemia (AML) and shows potential for FDA approval [7] - Bio-Path is advancing its pipeline with multiple candidates targeting various cancers and metabolic diseases [1][7] Company Overview - Bio-Path Holdings, Inc. is based in Bellaire, Texas and specializes in RNAi therapeutics [1] - The company employs a proprietary liposomal delivery system to enhance drug stability and cellular uptake while reducing toxicity [1] Pipeline Development - Prexigebersen (BP1001) targets the Grb2 protein and is currently in Phase 2 trials for AML [1] - A modified version, BP1001-A, is in Phase 1/1b trials for solid tumors and has shown early efficacy [7] - Another candidate, BP1002, targets the Bcl-2 protein for blood cancers and solid tumors [1] - Bio-Path is preparing an IND application for BP1003, a STAT3 inhibitor for pancreatic cancer [1]

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in GP2D human colorectal cancer cells; Company to conduct additional preclinical study focused on lung cancer cell linesGRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-dri ...

"We are honored to welcome Dr. Zamore to our Science Advisory Board," said Dr. Zdravka Medarova, Chief Scientific Officer and co-founder of TransCode Therapeutics. "His deep expertise in RNA biology and his track record of translating scientific discoveries into therapeutic innovations will be invaluable as we advance our pipeline of RNA-targeted cancer therapies." RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncology Dr. Zamore co-founded Alnyla ...

Core Insights - Biogen and City Therapeutics have announced a strategic collaboration to develop novel RNA interference (RNAi) therapies, combining Biogen's drug development expertise with City Therapeutics' RNAi engineering technologies [1][2][3] - The collaboration will initially focus on a target related to central nervous system diseases, utilizing advanced drug delivery technologies for systemic administration [2][3] - City Therapeutics will receive $46 million, including a $16 million upfront payment and a $30 million investment, with potential milestone payments of up to $1 billion based on development success [3] Company Overview - Biogen is a leading biotechnology company founded in 1978, focused on innovative science to deliver new medicines and create shareholder value [4] - City Therapeutics is a biopharmaceutical company specializing in next-generation RNAi technologies, aiming to expand the therapeutic reach of RNAi-based medicines [6]

HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (i ...